BR9913746C1 - Derivado de piridìnio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral,e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento - Google Patents
Derivado de piridìnio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral,e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimentoInfo
- Publication number
- BR9913746C1 BR9913746C1 BR9913746-1A BR9913746A BR9913746C1 BR 9913746 C1 BR9913746 C1 BR 9913746C1 BR 9913746 A BR9913746 A BR 9913746A BR 9913746 C1 BR9913746 C1 BR 9913746C1
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- treating
- aging
- treatment
- pharmaceutical composition
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 230000032683 aging Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000004509 Tooth Discoloration Diseases 0.000 abstract 1
- 206010044032 Tooth discolouration Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical class C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000036367 tooth discoloration Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"DERIVADO DE PIRIDìNIO, PROCESSO PARA A PREPARAçãO DO MESMO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA PREPARAçãO DE UMA FORMULAçãO PARENTERAL, E, MéTODOS DE TRATAMENTO DE UM PACIENTE DIABéTICO E DE PREVENçãO OU DE TRATAMENTO DE DOENçAS CAUSADAS POR DIABETES E POR COMPLICAçõES RELACIONADAS COM O ENVELHECIMENTO". A invenção descreve novos compostos da série de piridínio úteis para o tratamento da diabetes e de complicações vasculares relacionadas com o envelhecimento, incluindo doença renal, doença nervosa, aterosclerose, retinopatia, distúrbios dermatológicos e descoloração dos dentes, pela ruptura de AGE pré-formado, ou seus sais farmaceuticamente aceitáveis. A invenção também descreve o processo para a preparação de novos compostos da série e de composição farmacêutica compreendendo um ou mais destes compostos. A invenção descreve adicionalmente um processo de tratamento de um paciente diabético pela administração de compostos quer individualmente quer em combinação com drogas para terapia diabética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN828CA1999 | 1999-10-06 | ||
| PCT/IB1999/001683 WO2001025208A1 (en) | 1999-10-06 | 1999-10-15 | Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
Publications (8)
| Publication Number | Publication Date |
|---|---|
| BR9913746A BR9913746A (pt) | 2002-04-23 |
| BR9913746C1 true BR9913746C1 (pt) | 2002-08-13 |
| BR9913746B1 BR9913746B1 (pt) | 2013-03-19 |
| BR9913746E8 BR9913746E8 (pt) | 2018-05-02 |
| BR9913746F1 BR9913746F1 (pt) | 2020-07-07 |
| BRPI9913746B8 BRPI9913746B8 (pt) | 2021-05-25 |
| BR9913746F8 BR9913746F8 (pt) | 2021-11-30 |
| BRPI9913746F8 BRPI9913746F8 (pt) | 2022-01-18 |
Family
ID=11084928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRC19913746A BRPI9913746F8 (pt) | 1999-10-06 | 1999-10-15 | Derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6462057B1 (pt) |
| EP (1) | EP1222171B1 (pt) |
| JP (1) | JP4068843B2 (pt) |
| CN (1) | CN100355731C (pt) |
| AT (1) | ATE260256T1 (pt) |
| AU (1) | AU769940B2 (pt) |
| BR (1) | BRPI9913746F8 (pt) |
| CA (1) | CA2344144C (pt) |
| CZ (1) | CZ291789B6 (pt) |
| DE (1) | DE69915143T2 (pt) |
| DK (1) | DK1222171T3 (pt) |
| ES (1) | ES2216644T3 (pt) |
| HK (1) | HK1044335B (pt) |
| HU (1) | HU227523B1 (pt) |
| MX (1) | MXPA02003495A (pt) |
| PL (1) | PL211112B1 (pt) |
| PT (1) | PT1222171E (pt) |
| RU (1) | RU2215000C2 (pt) |
| WO (1) | WO2001025208A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020103228A1 (en) * | 1999-10-06 | 2002-08-01 | Torrent Pharmaceuticals Ltd. | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| CN100355731C (zh) * | 1999-10-06 | 2007-12-19 | 托伦脱药品有限公司 | 吡啶衍生物及其用途 |
| JP2004525904A (ja) * | 2000-12-29 | 2004-08-26 | アルテオン インコーポレイテッド | 線維性疾患又は他の適応症ｉｉｉｃの治療方法 |
| CZ303214B6 (cs) * | 2001-03-21 | 2012-05-30 | Torrent Pharmaceuticals Ltd | Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití |
| PT1243581E (pt) * | 2001-03-21 | 2005-11-30 | Torrent Pharmaceuticals Ltd | Compostos de piridinio uteis no tratamento de doencas relacionadas com age |
| CN1259316C (zh) | 2001-04-05 | 2006-06-14 | 托伦脱药品有限公司 | 用于老龄相关性和糖尿病性血管***并发症的杂环类化合物 |
| US20050043408A1 (en) * | 2001-10-15 | 2005-02-24 | Faustinus Yeboah | Anti-glycation agents for preventing age- diabetes- and smoking-related complications |
| HUP0104831A2 (hu) * | 2001-10-19 | 2003-08-28 | Torrent Pharmaceuticals Ltd. | Készítmény és eljárás piridíniumszármazékok gyógyászati alkalmazására |
| JP2007532677A (ja) * | 2004-04-16 | 2007-11-15 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ |
| WO2006002983A1 (en) * | 2004-07-06 | 2006-01-12 | Novartis Ag | Combination of organic compounds |
| GB2444593B (en) | 2006-10-05 | 2010-06-09 | Santarus Inc | Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations |
| US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
| RU2010135524A (ru) * | 2008-01-25 | 2012-02-27 | Торрент Фармасьютикалз Лтд. (In) | Фармацевтические комбинации |
| US20120058105A1 (en) | 2008-06-27 | 2012-03-08 | Martin Kean Chong Ng | Method of treatment of vascular complications |
| KR20120018185A (ko) | 2009-05-07 | 2012-02-29 | 토렌트 파마슈티칼스 리미티드 | 당뇨병 치료에 유용한 피페리딘 유도체 |
| AU2016246124B2 (en) * | 2015-04-08 | 2019-11-14 | Torrent Pharmaceuticals Limited | Pharmaceutical formulations |
| MX2017012943A (es) * | 2015-04-08 | 2018-01-30 | Torrent Pharmaceuticals Ltd | Nuevos compuestos de piridinio. |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH335521A (de) * | 1955-06-02 | 1959-01-15 | Cilag Ag | Verfahren zur Herstellung neuer quaternärer Salze |
| US4758583A (en) | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
| US5272176A (en) | 1984-03-19 | 1993-12-21 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
| US5137916A (en) | 1985-11-14 | 1992-08-11 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
| JPH05216151A (ja) * | 1992-02-06 | 1993-08-27 | Konica Corp | ハロゲン化銀写真感光材料 |
| US5656261A (en) | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
| JP4067562B2 (ja) * | 1995-01-18 | 2008-03-26 | アルテオン インコーポレイテッド | 進行性グリコシル化最終生成物の生成を阻止し、反転するためのチアゾリウム化合物の使用 |
| CN100355731C (zh) * | 1999-10-06 | 2007-12-19 | 托伦脱药品有限公司 | 吡啶衍生物及其用途 |
-
1999
- 1999-10-15 CN CNB998110388A patent/CN100355731C/zh not_active Expired - Fee Related
- 1999-10-15 EP EP99973986A patent/EP1222171B1/en not_active Expired - Lifetime
- 1999-10-15 DE DE69915143T patent/DE69915143T2/de not_active Expired - Lifetime
- 1999-10-15 WO PCT/IB1999/001683 patent/WO2001025208A1/en active IP Right Grant
- 1999-10-15 ES ES99973986T patent/ES2216644T3/es not_active Expired - Lifetime
- 1999-10-15 MX MXPA02003495A patent/MXPA02003495A/es active IP Right Grant
- 1999-10-15 AT AT99973986T patent/ATE260256T1/de active
- 1999-10-15 DK DK99973986T patent/DK1222171T3/da active
- 1999-10-15 BR BRC19913746A patent/BRPI9913746F8/pt not_active IP Right Cessation
- 1999-10-15 CZ CZ20011033A patent/CZ291789B6/cs not_active IP Right Cessation
- 1999-10-15 CA CA002344144A patent/CA2344144C/en not_active Expired - Fee Related
- 1999-10-15 PT PT99973986T patent/PT1222171E/pt unknown
- 1999-10-15 RU RU2001107007/04A patent/RU2215000C2/ru active
- 1999-10-15 JP JP2001528154A patent/JP4068843B2/ja not_active Expired - Lifetime
- 1999-10-15 HU HU0104116A patent/HU227523B1/hu unknown
- 1999-10-15 AU AU59942/99A patent/AU769940B2/en not_active Ceased
- 1999-10-15 PL PL348327A patent/PL211112B1/pl unknown
-
2000
- 2000-06-21 US US09/598,410 patent/US6462057B1/en not_active Expired - Lifetime
-
2002
- 2002-08-09 US US10/214,704 patent/US6624178B2/en not_active Expired - Fee Related
- 2002-08-12 HK HK02105889.1A patent/HK1044335B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9913746C1 (pt) | Derivado de piridìnio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral,e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento | |
| Callaham | Tricyclic antidepressant overdose | |
| JPH0222229A (ja) | 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤 | |
| BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
| BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| ATE508738T1 (de) | System zur beabstandeten abgabe von arzneimitteln | |
| BR0013065A (pt) | Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos | |
| RU94022479A (ru) | Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат | |
| JP6676062B2 (ja) | 認知低下を処置するための方法 | |
| PT1212060E (pt) | Utilizacao de nicotina ou dos seus derivados e de l-dopa num medicamento para o tratamento de doencas neurologicas, em especial a doenca de parkinson | |
| US11077118B2 (en) | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake | |
| CY1115269T1 (el) | Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους | |
| KR100535554B1 (ko) | 소아과 수술에서의 레보부피바카인의 용도 | |
| NL8320240A (nl) | Verbeterde analgetische en antiflogistische, caffeine-bevattende preparaten en werkwijzen voor de toepassing daarvan. | |
| BR9915962A (pt) | Composto da série do piridìnio, processos para a preparação de composto da série do piridìnio e de uma formulação parenteral, uso de um composto, composição farmacêutica para tratar complicações diabéticas e doenças associadas ao envelhecimento, e, método para tratar um paciente diabético e para prevenir ou tratar doenças causadas por complicações associadas à diabetes e ao envelhecimento | |
| PT1243581E (pt) | Compostos de piridinio uteis no tratamento de doencas relacionadas com age | |
| WO2016053121A1 (en) | Antiviral pharmaceutical formulation for the treatment of dengue, influenza and hiv/aids | |
| SK286260B6 (sk) | Ošetrovanie migrény podávaním kyseliny alfa-lipoovej alebo jej derivátov | |
| JP2008169220A (ja) | 癌を処置または予防するためのβ−ラパコンの使用 | |
| JP5685362B2 (ja) | 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン | |
| Trope et al. | Systemic absorption of topical and subconjunctival gentamicin. | |
| Alipour et al. | Comparison of Analgesic Effects of B Vitamins and Diclofenac plus B Vitamins During General Anesthesia and PACU | |
| RU2208402C1 (ru) | Способ профилактики тромбоза сосудов пересаженного лоскута | |
| DE102004040630A1 (de) | Kombinationstherapie mit Procain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 10A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B03H | Publication of an application: rectification [chapter 3.8 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFENTE A RPI 1649 DE 13/08/2002.QUANTO AOS ITENS (54 E 71). Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B03H | Publication of an application: rectification [chapter 3.8 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 15/10/2019 |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A RPI 2583 DE 07/07/2020, QUANTO AO ITEM (54) TITULO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/1999, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PATENTE EXTINTA EM 15/10/2019 |